About the company

The Swiss healthcare system is expensive and inefficient: only 3% of expenditure is channelled into prevention, although 80% of healthcare costs are caused by chronic diseases that are often preventable. This is precisely where CARE comes in. What used to be accessible only via doctors' appointments, paper printouts with lab results and medical jargon can now be tracked more easily, comprehensibly and digitally. Since our foundation in 2022, we have been strengthening people's health literacy with easily accessible health tests, an intelligent app and medical expertise. This enables everyone to track, understand and act on their health before symptoms arise.

More and more people are looking for more control over their health - as can be seen from the boom in wearables that record sleep, activity and heart rate data. The next milestone in preventive healthcare is now imminent: the digital tracking of scientifically based biomarkers such as cholesterol, blood sugar, muscle mass, micronutrients and much more.

CARE focuses on medically evidence-based markers. That is why we are supported by leading insurance companies. Thanks to partnerships with the largest laboratory chains in Switzerland, we can expand quickly and efficiently. Over 3,000 people already use CARE. With sales of over CHF 4 million, strong partners and a validated product, we are ready for the next stage of growth - in Switzerland and beyond. 

Company overview

• Strong growth & profitable: sales growth from CHF 0.9 million (2023) to CHF 1.7 million (2024) and forecast CHF 5.0 million in 2025 - this corresponds to a CAGR of 113%. The margin after cost of sales is over 50% - with falling costs thanks to AI-supported automation.
  
  
• Popular & recommended: Over 3,000 customers, 4.7 stars on Google - 26 % of all purchases come from returning customers, with a strong upward trend.
  
  
• Recognised & in partnership: CARE is supported by leading supplementary insurance companies - they cover up to 90 % of the costs and actively recommend CARE to their policyholders.
  
  
• Flexible & scalable: We open up new locations within a week with investment costs of less than CHF 10,000. Thanks to strong laboratory partners, infrastructure and personnel are outsourced.

Advantages for co-owners and investors

As a co-owner of CARE you benefit from these advantages:

• Attractive growth market: You are investing in a fast-growing sector with high social relevance. Prevention is becoming the central pillar of modern healthcare systems.
  
  
• Strong network: CARE is supported by renowned investors - including entrepreneurs, VC partners, professional athletes such as Kevin Fiala and Yann Sommer as well as medical experts.
  
• Innovation potential: You will be involved in a leading AI-supported platform for preventive health with enormous growth and scaling potential.
  
  
• Experienced founding team: The team combines expertise in medicine, technology and company building - with successful exits in the three-digit million range.

We are looking for investors who are interested in digital health, AI technology and innovative, scalable business models and who want to play an active role in shaping our vision of a healthy society.

Milestones

Testimonials

“Since I joined CARE I can really track, understand and improve my inner health.
It’s a gamechanger and it has a huge impact on my performance.”

Kevin Fiala, professional Swiss ice hockey player in the NHL with the Los Angeles Kings
Find out more about Kevin's experience with CARE here.

“If you want to grow old healthily, you need to know the right levers early on.
CARE offers a modern basis for making prevention truly effective.”

Dr. Andreas Müller, mediacal specialist in gastroenterology, Klinik Hirslanden

“I am impressed by how CARE translates complex health information into a clear,
medically founded  structure - a real step forward for prevention.”

 Dr. Anna Erat MD/PhD,  Specialist in internal medicine, sports physician and longevity expert

“CARE shows how personalised medicine works in practice - individually, digitally and scientifically based.”

Karin Bosshard, PhD, Strategy Leader personalized Medizin, Roche

“Those who actively use their health data can benefit from personalised prevention.
CARE paves a promising path here: evidence-based, impact-orientated, digital and human at the same time.“

Prof. Dr. Elgar Fleisch, Co-Chair Center for Digital Health Interventions, ETH Zürich

Our vision - Why invest in CARE?

We make health accessible and understandable for everyone.

Your investment will help us to achieve the following goals:

• Market penetration: Expand market presence throughout Switzerland, including western Switzerland with additional laboratory locations.
  
  
• Digital applications: Further development of the AI agent and integration of wearables as well as the upload of historical health data.
  
  
• Product range expansion: Introduction of further additional products and development of the health platform to increase customer lifetime value.
  
• International expansion: Planning market entry into new, international markets in order to further publicise our vision. 

Our crowd-investing campaign is a central building block on the way to the planned Series A financing round in 2025/2026.

FAQ

Why did you decide in favour of crowdinvesting as financing?

Because health affects us all - and everyone can be part of the solution. With crowdinvesting, we are opening up CARE to a committed community and also enabling smaller investors to participate and benefit from our success. At the same time, we are creating a strong basis for organic growth: through personal recommendations, network effects and new brand ambassadors from among our users.

How did you come up with the company valuation?

The valuation of CHF 15.5 million is based on the sales multiplier method. Based on our realised turnover of CHF 1.7 million in 2024, this results in a multiplier of 9.1x. Taking into account the strong sales growth in the first quarter of 2025 (CHF 582k with five active locations), linear extrapolation - without additional location openings - results in annual sales of over CHF 2.3 million, corresponding to a multiplier of 6.7x.

As we are currently in the scaling phase and plan to have 10 active locations by the end of 2025, we expect sales of around CHF 5.0 million for 2025 as a whole. On this basis, the effective sales multiple is reduced to 3.1x - a conservative value compared to standard market multiples for high-growth digital health platforms.

In comparison, the US company Function Health, which pursues a similar value proposition in the field of preventive diagnostics, is valued at around USD 2.5 billion with estimated annual sales of USD 100 million - which corresponds to a multiple of around 25x.

Do I have voting rights? 

No, crowdinvesting is carried out without voting rights. Strategic decisions remain with the founding team and the management - so we can act efficiently and flexibly.

Will I receive dividends?

No dividend payment is currently planned. We invest specifically in growth. Investors will receive a financial return in the event of an exit or sale of shares.

Is an exit planned?

In the long term, yes. The aim is to make CARE so successful that a sale to a strategic partner such as Labore or an IPO will be possible - with a corresponding profit for all investors.

What Are Preferred Participation Certificates?

A Preferred Participation Certificate is a type of participation certificate, meaning it is an equity security without voting rights, that is economically equivalent to preferred shares. In other words, it ranks pari passu with preferred shareholders, meaning holders of Preferred Participation Certificates enjoy the same economic rights as holders of preferred shares.

Are There Provisions in the Event of a Sale (Tag-Along / Drag-Along Rights)?

Yes, there are provisions in place to protect and bind minority investors. Holders of participation certificates are entitled to tag-along rights and are subject to drag-along obligations, each of which are linked to the corresponding provisions of the Shareholders’ Agreement.

How Is the Liquidation Preference Structured for Preferred Participation Certificates?

Preferred Participation Certificates carry a 1x non-participating liquidation preference. This means that in the event of a sale or IPO, you will receive at least your invested capital back before any distributions are made to other shareholders. However, if the per-share exit proceeds exceed your initial investment, you will naturally receive the higher amount.

We cannot solve this problem alone - it needs a movement.

With your investment, you become part of this movement: You are helping to create a new awareness of prevention and bring real preventive healthcare to where it is lacking today - into people's everyday lives.

Health needs new approaches - and strong partners at your side.

We have the right product, the momentum, an experienced team and the support of leading insurance and laboratory partners. Together with you, we create access to modern preventive care - scalable, evidence-based and for everyone.

Become part of the movement - invest in CARE now and shape the future of medicine.